logo

NVNO

enVVeno Medical·NASDAQ
--
--(--)
--
--(--)
1.61 / 10
Underperform

Financial analysis yields a poor rating (1.6/10). Key weaknesses include negative Revenue-MV (-0.2574) and Net income-Revenue (-0.1668) factors, a low ROA (-40.7109%), and an Asset-MV deficit (-0.5007). Positive aspects such as strong cash position (Cash-UP) and 100% Net profit attributable to shareholders are outweighed by these structural issues, leading to a negative fundamental outlook.

Fundamental(1.61)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.26
Score0/3
Weight16.51%
1M Return-3.84%
ROA (%)
Value-40.71
Score2/3
Weight1.74%
1M Return-0.39%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight7.56%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight10.68%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight18.44%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-54.28
Score2/3
Weight1.74%
1M Return-0.39%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight8.53%
1M Return-1.95%
Asset-MV
Value-0.50
Score1/3
Weight2.97%
1M Return-0.63%
Cash-MV
Value-0.07
Score1/3
Weight20.26%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight11.57%
1M Return-2.89%
Is NVNO fundamentally strong?
  • NVNO scores 1.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -43.95% ROE, 0.00% net margin, -0.31 P/E ratio, 0.23 P/B ratio, and 16.28% earnings growth, these metrics solidify its Underperform investment rating.